FDA Clears First mRNA Flu Vaccine for Adults 50 and Older

The country's first mRNA-based influenza vaccine is cleared for use this fall, but what that clearance actually covers depends heavily on how old you are.

On August 5, the FDA approved Moderna's mFLUSIVA for adults ages 50 to 64, a full approval based on late-stage trial data. For adults 65 and older, the picture is different. As reported by NPR and confirmed in Moderna's own release, the agency granted only accelerated approval for that group, based on a smaller immunogenicity study rather than a completed efficacy trial. Moderna has agreed to run an additional study and submit more data in the 65-and-up population before full approval can follow.

The distinction matters at the bedside. Accelerated approval means the agency judged the vaccine's antibody response a reasonable surrogate for protection, but the harder outcome data, things like hospitalizations prevented in actual 70-year-olds over an actual flu season, aren't in yet. Clinicians talking to patients in that age group should be clear about what the evidence does and doesn't show.

On the efficacy side, the numbers from the 50-to-64 trial are notable. According to reporting reviewed by NBC News, mFLUSIVA was found to be about 27% more effective than a standard flu shot in late-stage trials. In the older cohort, Moderna reported the vaccine generated stronger antibody responses than Sanofi's high-dose flu vaccine, which has been the go-to for that age group.

The technology itself is not new to anyone who got a Covid-19 shot. As Harvard Health Publishing explained in coverage of the approval, mFLUSIVA uses a short strand of genetic code to instruct the body to produce a flu protein and trigger an immune response, rather than relying on inactivated virus grown in eggs or cells. One practical advantage: mRNA vaccines can be reformulated faster when circulating strains shift late in the production window, a real limitation of traditional manufacturing.

The road to this approval was not smooth. As CNN reported, the FDA initially declined to review Moderna's application at all, with the agency's top vaccine regulator citing objections to Moderna's choice of comparator vaccine. The reversal came after the agency's independent vaccine advisers voted unanimously in June that the vaccine's benefits outweigh its risks. Separately, the Trump administration cut federal mRNA vaccine development funding through BARDA earlier this year, framing the decision as a shift toward what HHS described as "other vaccine platforms."

All of that context sits in the background as pharmacies prepare to stock the shot. Moderna said it expects mFLUSIVA to be available at select retailers in time for the 2026-2027 respiratory virus season. Local availability may lag, though, and insurance coverage terms are still being sorted out in many markets.

For patients ages 50 to 64, the conversation with their primary care physician or pharmacist is fairly straightforward: there's a new option, the trial data are solid, and side effects were more common than with traditional shots but serious adverse events were not. For patients 65 and older, the conversation needs a little more nuance. The accelerated approval pathway got the vaccine to them this season; the full evidence base for their age group is still being built.

Sources cited:
- Harvard Health Publishing (https://www.health.harvard.edu/immune-and-infectious-diseases/fda-approves-first-mrna-based-flu-vaccine)
- NPR (https://www.npr.org/2026/08/06/nx-s1-5923342/moderna-mrna-flu-vaccine)
- NBC News (https://www.nbcnews.com/health/health-news/fda-approves-1st-mrna-flu-shot-moderna-rcna590599)
- CNN (https://www.cnn.com/2026/08/14/health/first-mrna-flu-vaccine)
- Healthline (https://www.healthline.com/health-news/fda-approves-first-mrna-flu-vaccine-older-adults)
- Forbes (https://www.forbes.com/sites/siladityaray/2026/08/06/fda-approves-first-mrna-flu-vaccine-for-older-adults/)